Oncosil Medical Share Price and Company Fundamentals
Last traded: Today at 4:38 AM
OncoSil Medical Limited, a medical device company, focuses on the development of localized treatments for pancreatic and liver cancer in Australia. Its lead product is OncoSil, a brachytherapy device that implants a pre-determined dose of beta radiation directly into cancerous tissue for the treatment of cancer. The company was formerly known as NeuroDiscovery Limited and changed its name to OncoSil Medical Limited in June 2013. OncoSil Medical Limited is headquartered in North Sydney, Australia.
|Primary activities||Oncology Research and Development|
|Industry / Sector||Medical Devices / Healthcare|
|Mailing address||15 Blue Street Suite 503 Level 5 North Sydney NSW 2060 Australia|
|Phone / Fax||61 2 9223 3344 / 61 2 9252 3988|
|Share registry||BOARDROOM PTY LIMITED|
Oncosil Medical does not pay dividends.
As of May 2021, following are the company executives and directors listed on Oncosil Medical.
|Mr. Karl David Pechmann||CFO & Company Sec.||305.31k|
|Mr. Nigel Lange||CEO, MD & Pres of EMEA|
|Mr. Michael Warrener||Global Sales & Marketing Director|
|Dr. David Charles James||Global Head of Manufacturing Operations|
|Mr. Charles Rowland||Pres of US Operations||69|
|Dr. Ralph Peters||Chief Medical Officer|
|Mr. David Turner||Head of Medical Affairs|
Profitability and management effectiveness
Return on assets
Return on equity
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Oncosil Medical is 67.01M and its enterprise value is 62.08M. The enterprise value to revenue ratio of OSL is 28.02.
The OSL's stocks Beta value is 0.15 making it 85% less volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.
Companies similar to Oncosil Medical (OSL)
Oncosil Medical (ASX:OSL) Frequently Asked Questions
1. What is Oncosil Medical's Stock Symbol?
Oncosil Medical trades on ASX under the ticker symbol "OSL".
2. What is Oncosil Medical's stock price today?
One share of OSL stock can currently be purchased for approximately $0.083.
3. How can I contact Oncosil Medical?
Oncosil Medical's mailing address is 15 Blue Street Suite 503 Level 5 North Sydney NSW 2060 Australia. The company can be reached via phone at 61 2 9223 3344.
4. What is Oncosil Medical's official website?
The official website of Oncosil Medical is http://www.oncosil.com.au.
5. Which share registry manages Oncosil Medical's stock?
Oncosil Medical's stock is managed by BOARDROOM PTY LIMITED.